Home  |  Contact

UniProtKB/Swiss-Prot Q05315: Variant p.Ala28Val

Galectin-10
Gene: CLC
Variant information

Variant position:  28
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Polymorphism
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Alanine (A) to Valine (V) at position 28 (A28V, p.Ala28Val).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from small size and hydrophobic (A) to medium size and hydrophobic (V)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  28
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  142
The length of the canonical sequence.

Location on the sequence:   YTEAASLSTGSTVTIKGRPL  A CFLNEPYLQVDFHTEMKEES
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 2 – 142 Galectin-10
Domain 6 – 138 Galectin
Beta strand 18 – 28


Literature citations

Molecular cloning and characterization of human eosinophil Charcot-Leyden crystal protein (lysophospholipase). Similarities to IgE binding proteins and the S-type animal lectin superfamily.
Ackerman S.J.; Corrette S.E.; Rosenberg H.F.; Bennett J.C.; Mastrianni D.M.; Nicholson-Weller A.; Weller P.F.; Chin D.T.; Tenen D.G.;
J. Immunol. 150:456-468(1993)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; PROTEIN SEQUENCE OF 3-18 AND 93-110; VARIANT VAL-28;

Localization of the human eosinophil Charcot-Leyden crystal protein (lysophospholipase) gene (CLC) to chromosome 19 and the human ribonuclease 2 (eosinophil-derived neurotoxin) and ribonuclease 3 (eosinophil cationic protein) genes (RNS2 and RNS3) to chromosome 14.
Mastrianni D.M.; Eddy R.L.; Rosenberg H.F.; Corrette S.E.; Shows T.B.; Tenen D.G.; Ackerman S.J.;
Genomics 13:240-242(1992)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANT VAL-28;

The genomic structure of the human Charcot-Leyden crystal protein gene is analogous to those of the galectin genes.
Dyer K.D.; Handen J.S.; Rosenberg H.F.;
Genomics 40:217-221(1997)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANT VAL-28;

A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death.
Than N.G.; Romero R.; Goodman M.; Weckle A.; Xing J.; Dong Z.; Xu Y.; Tarquini F.; Szilagyi A.; Gal P.; Hou Z.; Tarca A.L.; Kim C.J.; Kim J.S.; Haidarian S.; Uddin M.; Bohn H.; Benirschke K.; Santolaya-Forgas J.; Grossman L.I.; Erez O.; Hassan S.S.; Zavodszky P.; Papp Z.; Wildman D.E.;
Proc. Natl. Acad. Sci. U.S.A. 106:9731-9736(2009)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; TISSUE SPECIFICITY; VARIANT VAL-28;

The DNA sequence and biology of human chromosome 19.
Grimwood J.; Gordon L.A.; Olsen A.S.; Terry A.; Schmutz J.; Lamerdin J.E.; Hellsten U.; Goodstein D.; Couronne O.; Tran-Gyamfi M.; Aerts A.; Altherr M.; Ashworth L.; Bajorek E.; Black S.; Branscomb E.; Caenepeel S.; Carrano A.V.; Caoile C.; Chan Y.M.; Christensen M.; Cleland C.A.; Copeland A.; Dalin E.; Dehal P.; Denys M.; Detter J.C.; Escobar J.; Flowers D.; Fotopulos D.; Garcia C.; Georgescu A.M.; Glavina T.; Gomez M.; Gonzales E.; Groza M.; Hammon N.; Hawkins T.; Haydu L.; Ho I.; Huang W.; Israni S.; Jett J.; Kadner K.; Kimball H.; Kobayashi A.; Larionov V.; Leem S.-H.; Lopez F.; Lou Y.; Lowry S.; Malfatti S.; Martinez D.; McCready P.M.; Medina C.; Morgan J.; Nelson K.; Nolan M.; Ovcharenko I.; Pitluck S.; Pollard M.; Popkie A.P.; Predki P.; Quan G.; Ramirez L.; Rash S.; Retterer J.; Rodriguez A.; Rogers S.; Salamov A.; Salazar A.; She X.; Smith D.; Slezak T.; Solovyev V.; Thayer N.; Tice H.; Tsai M.; Ustaszewska A.; Vo N.; Wagner M.; Wheeler J.; Wu K.; Xie G.; Yang J.; Dubchak I.; Furey T.S.; DeJong P.; Dickson M.; Gordon D.; Eichler E.E.; Pennacchio L.A.; Richardson P.; Stubbs L.; Rokhsar D.S.; Myers R.M.; Rubin E.M.; Lucas S.M.;
Nature 428:529-535(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]; VARIANT VAL-28;

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]; VARIANT VAL-28;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.